728 x 90

Revolutionary Lung Cancer Detection Technology Shatters Barriers: DELFI Diagnostics Study Unveils Game-Changing Breakthrough

Revolutionary Lung Cancer Detection Technology Shatters Barriers: DELFI Diagnostics Study Unveils Game-Changing Breakthrough

DELFI Diagnostics is making significant strides in the field of cancer detection with their breakthrough technology and completed clinical study in lung cancer detection. By applying advanced machine learning technology to whole-genome sequencing data, DELFI is able to compare an individual’s cell-free DNA patterns and characteristics against populations with and without cancer. This approach has the potential to revolutionize early cancer detection, particularly for lung cancer, which is the leading cause of cancer death globally.

In an effort to raise awareness about their innovative test, DELFI will be participating in multiple sessions at the HLTH 2023 conference in Las Vegas and the CHEST 2023 Annual Meeting in Honolulu. At HLTH, the company will provide a critical update on the progress of their lung cancer detection test for screen-eligible individuals, as well as share insights on the evolving liquid biopsy landscape during a Tech Talk presentation and a panel discussion.

Additionally, DELFI will present new data from their DELFI-L101 Study, a prospective, multicenter, case-control study aimed at training and independently validating the blood-based test for early cancer detection. This oral presentation at the CHEST Annual Meeting will shed light on the effectiveness of DELFI’s test in identifying lung cancer in individuals eligible for lung cancer screening.

With only six percent of eligible Americans undergoing lung cancer screening annually, DELFI’s accessible and accurate blood-based test has the potential to make a significant impact on population health. By detecting cancer in its earliest stages, DELFI aims to address the unmet needs of early cancer detection on a larger scale.

DELFI’s commitment to solving high-burden population health issues, starting with lung cancer, is evident through their participation in these conferences. Their presence at HLTH and CHEST provides a timely opportunity to reveal new insights and advancements in their mission to detect cancer in its earliest stages accurately and accessibly.

In conclusion, DELFI Diagnostics’ breakthrough technology and completed clinical study in lung cancer detection are poised to revolutionize early cancer detection. Their participation in the HLTH 2023 conference and the CHEST 2023 Annual Meeting demonstrates their commitment to addressing the unmet needs of early cancer detection and improving population health. With their innovative approach, DELFI has the potential to make a significant impact in the fight against lung cancer, the leading cause of cancer death worldwide.

Avatar of Nayan Kumar
Nayan Kumar
CONTRIBUTOR
PROFILE